We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Neovasc Inc | NASDAQ:NVCN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 30.03 | 27.70 | 30.00 | 0 | 01:00:00 |
Securities and Exchange Commission
w ashington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of |
June | 2019 | |
Commission File Number |
001-36458 | ||
Neovasc Inc. |
|||
(Translation of registrant’s name into English) | |||
Suite 5138 - 13562 Maycrest Way Richmond, British Columbia, Canada, V6V 2J7 |
|||
(Address of principal executive offices) |
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F |
☒ |
Form 40-F |
☐ |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
DOCUMENTS INCLUDED AS PART OF THIS REPORT
Document | ||
Document 1 | News Release dated June 4, 2019 - Neovasc Inc. Reports Results of Annual General and Special Meeting of Shareholders and Provides Update on Neovasc Reducer™ | |
DOCUMENT 1
Neovasc Inc. Reports Results of Annual General and Special Meeting of Shareholders and Provides Update on Neovasc Reducer™
NASDAQ, TSX: NVCN
VANCOUVER, June 4, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) is pleased to announce the results of the votes on matters considered at its Annual General and Special Meeting of Shareholders held on June 4, 2019 in Vancouver, B.C. (the "Meeting").
At the Meeting, the shareholders of the Company (the "Shareholders") re-elected board members Steven Rubin, Paul Geyer, Doug Janzen, Dr. Jane Hsiao and Alexei Marko and elected Fred Colen to serve in office until the next annual meeting or until their successors are duly elected or appointed. Detailed results of the voting in respect of the election of directors are as follows:
Nominee | Votes For | % Votes For | Votes Withheld | % Votes Withheld |
Steven Rubin | 12,084,700 | 62.83 | 7,148,196 | 37.17 |
Paul Geyer | 18,385,393 | 95.59 | 847,503 | 4.41 |
Doug Janzen | 18,310,988 | 95.21 | 921,908 | 4.79 |
Dr. Jane Hsiao | 11,916,268 | 61.96 | 7,316,628 | 38.04 |
Alexei Marko | 16,895,232 | 87.85 | 2,337,664 | 12.15 |
Fred Colen | 18,583,805 | 96.63 | 649,091 | 3.37 |
At the Meeting, the Shareholders also approved resolutions authorizing the Company's Board of Directors to, at their discretion, execute a common share consolidation (72.43% of votes cast in favour) and re-appointing Grant Thornton LLP, Chartered Accountants as auditors of the Company.
Neovasc Reducer
™
("Reducer")
update
As previously announced during Neovasc's first quarter 2019 earnings call, the Company confirms that a U.S. Food and Drug Administration
("FDA") Sprint discussion took place in May to discuss our approach to demonstrating long term Reducer fatigue life.
A further FDA Sprint discussion about clinical strategy is scheduled to be held on June 26, 2019.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular
marketplace. Its products include the Reducer, for the treatment of refractory angina, which is not currently commercially available
in the United States and has been commercially available in Europe since 2015, and the Tiara™, for the transcatheter treatment
of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe. For more information,
visit: www.neovasc.com.
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact, including without limitation
statements containing the words "believe", "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect" and similar expressions. Forward-looking statements
may involve, but are not limited to, beliefs and expectations relating to whether the Board of Directors of the Company will elect
to execute a common share consolidation, future FDA Sprint discussions and the growing cardiovascular marketplace. Many factors
and assumptions could cause the Company's actual results, performance or achievements to differ materially from those expressed
or implied by the forward-looking statements, including, without limitation, the substantial doubt about the Company's ability
to continue as a going concern; risks relating to the Notes issued pursuant to the 2017 Financing, resulting in significant dilution
to the Company's shareholders; risks relating to the Company's need for significant additional future capital and the Company's
ability to raise additional funding; risks relating to cashless exercise and adjustment provisions in the Notes issued pursuant
to the 2017 Financing, which could make it more difficult and expensive for the Company to raise additional capital in the future
and result in further dilution to investors; risks relating to the sale of a significant number of Common Shares of the Company;
risks relating to the conversion of the senior secured convertible notes (the "Notes") issued pursuant to the November
2017 private placement (the "2017 Financing"), which may encourage short sales by third parties; risks relating to the
possibility that the Common Shares of the Company may be delisted from the Nasdaq Capital Market or the Toronto Stock Exchange,
which could affect their market price and liquidity; risks relating to the Company's conclusion that it did not have effective
internal control over financial reporting as at December 31, 2018; risks relating to the Company's Common Share price being volatile;
risks relating to the influence of significant shareholders of the Company over the Company's business operations and share price;
risks relating to the Company's significant indebtedness, and its effect on the Company's financial condition; risks relating to
claims by third parties alleging infringement of their intellectual property rights; risks relating to lawsuits that the Company
is subject to, which could divert the Company's resources and result in the payment of significant damages and other remedies;
the Company's ability to establish, maintain and defend intellectual property rights in the Company's products; risks relating
to results from clinical trials of the Company's products, which may be unfavorable or perceived as unfavorable; the Company's
history of losses and significant accumulated deficit; risks associated with product liability claims, insurance and recalls; risks
relating to use of the Company's products in unapproved circumstances, which could expose the Company to liabilities; risks relating
to competition in the medical device industry, including the risk that one or more of the Company's competitors may develop more
effective or more affordable products; risks relating to the Company's ability to achieve or maintain expected levels of market
acceptance for the Company's products, as well as the Company's ability to successfully build its in-house sales capabilities or
secure third-party marketing or distribution partners; the Company's ability to convince public payors and hospitals to include
the Company's products on their approved products lists; risks relating to new legislation, new regulatory requirements and the
efforts of governmental and third-party payors to contain or reduce the costs of healthcare; risks relating to increased regulation,
enforcement and inspections of participants in the medical device industry, including frequent government investigations into marketing
and other business practices; risks associated with the extensive regulation of the Company's products and trials by governmental
authorities, as well as the cost and time delays associated therewith; risks associated with post-market regulation of the Company's
products; health and safety risks associated with the Company's products and industry; risks associated with the Company's manufacturing
operations, including the regulation of the Company's manufacturing processes by governmental authorities and the availability
of two critical components of the Reducer; risk of animal disease associated with the use of the Company's products; risks relating
to the manufacturing capacity of third-party manufacturers for the Company's products, including risks of supply interruptions
impacting the Company's ability to manufacture its own products; risks relating to the Company's dependence on limited products
for substantially all of the Company's current revenues; risks relating to the Company's exposure to adverse movements in foreign
currency exchange rates; risks relating to the possibility that the Company could lose its foreign private issuer status under
U.S. federal securities laws; risks relating to breaches of anti-bribery laws by the Company's employees or agents; risks associated
with future changes in financial accounting standards and new accounting pronouncements; risks relating to the Company's dependence
upon key personnel to achieve its business objectives; the Company's ability to maintain strong relationships with physicians;
risks relating to the sufficiency of the Company's management systems and resources in periods of significant growth; risks associated
with consolidation in the health care industry, including the downward pressure on product pricing and the growing need to be selected
by larger customers in order to make sales to their members or participants; risks relating to the Company's ability to successfully
identify and complete corporate transactions on favorable terms or achieve anticipated synergies relating to any acquisitions or
alliances; risks relating to the Company's ability to successfully enter into fundamental transactions as defined in the Notes
issued pursuant to the 2017 Financings; anti-takeover provisions in the Company's constating documents which could discourage a
third party from making a takeover bid beneficial to the Company's shareholders; and risks relating to conflicts of interests among
the Company's officers and directors as a result of their involvement with other issuers. These risk factors and others relating
to the Company are discussed in greater detail in the "Risk Factors" section of the Company's Annual Report on Form 20-F
and in the Management's Discussion and Analysis for the three months ended March 31, 2019 (copies of which may be obtained at www.sedar.com
or www.sec.gov). The Company has no intention and undertakes no obligation to update or revise any forward-looking statements beyond
required periodic filings with securities regulators, whether as a result of new information, future events or otherwise, except
as required by law.
View original content:http://www.prnewswire.com/news-releases/neovasc-inc-reports-results-of-annual-general-and-special-meeting-of-shareholders-and-provides-update-on-neovasc-reducer-300861856.html
SOURCE Neovasc Inc.
View original content: http://www.newswire.ca/en/releases/archive/June2019/04/c4475.html
%CIK: 0001399708
For further information: Chris Clark, Chief Financial Officer, Neovasc Inc., 604 248-4138, cclark@neovasc.com; Jeremy Feffer, LifeSci Advisors, LLC, 212-915-2568, jeremy@lifesciadvisors.com
CO: Neovasc Inc.
CNW 14:15e 04-JUN-19
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Neovasc Inc. | |||||
(Registrant) | |||||
Date: |
June 4, 2019 |
|
By: |
/s/ Chris Clark
|
|
Name: Chris Clark Title: Chief Financial Officer
|
|||||
1 Year Neovasc Chart |
1 Month Neovasc Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions